Dialog Box

Loading...

PBAC Submission of Galafold™ (migalastat) for Fabry disease

25 Aug 2017 at 12:00AM
Category: Fabry Australia News

Following on from the recent news that the Australian Therapeutic Goods Administration (TGA) approve Galafold™ (migalastat) for the treatment of Fabry Disease. Refer to Fabry Australia’s public statement.

The Pharmaceutical Benefits Advisory Committee (PBAC) are considering Galafold™ (migalastat) for the treatment of Fabry Disease for listing as a new medicine in Australia as part of its agenda for the next PBAC meeting which will be held in November 2017. You can help! The public (including Fabry patients/ families/ friends / doctors) are invited to provide feedback via an online submission.

Press the following link to complete the online form and for further information on how to complete your submission; http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form

The closing date for community feedback is 4 October 2017. 

For further information and details contact Fabry Australia

Category: Fabry Australia News
Tags: